377 related articles for article (PubMed ID: 9070503)
1. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
2. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.
Gordon LI; Young M; Weller E; Habermann TM; Winter JN; Glick J; Ghosh C; Flynn P; Cassileth PA
Blood; 1999 Nov; 94(10):3307-14. PubMed ID: 10552939
[TBL] [Abstract][Full Text] [Related]
4. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
6. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
7. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
[TBL] [Abstract][Full Text] [Related]
8. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
[TBL] [Abstract][Full Text] [Related]
12. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
13. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
14. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
[TBL] [Abstract][Full Text] [Related]
15. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
16. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with MECOP-B for intermediate-grade and high-grade non-Hodgkin's lymphoma in Saudi Arabia: clinical results and analysis of prognostic factors.
Ibrahim EM; Bunyan RF; al-Mulhim FA; al-Nabhan AA; Ibrahim RE
Acta Haematol; 1996; 96(3):126-34. PubMed ID: 8876608
[TBL] [Abstract][Full Text] [Related]
18. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
Witzig TE; Camoriano JK; Schroeder G; Kurtin PJ; Habermann TM
Leuk Lymphoma; 1998 Jan; 28(3-4):307-14. PubMed ID: 9517502
[TBL] [Abstract][Full Text] [Related]
20. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial.(PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology).
Montserrat E; García-Conde J; Viñolas N; López-Guillermo A; Hernández-Nieto L; Zubizarreta A; Maldonado J; Alcalá A; Faura MV; Llorente A; Bladé J; Fontanillas M; Estapé J
Eur J Haematol; 1996 Nov; 57(5):377-83. PubMed ID: 9003479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
